Treatment of Active Crohn's Disease With an Ordinary Food-based Diet That Replicates Exclusive Enteral Nutrition

Gastroenterology

Volumn 156, Issue 5, 2019, Pages 1354-1367.e6

  Svolos, Vaios ^a   Hansen, Richard ^b   Nichols, Ben ^a   Quince, Christopher ^c   Ijaz, Umer Z ^a   Papadopoulou, Rodanthi T ^a   Edwards, Christine A ^a   Watson, David ^d   Alghamdi, Adel ^d   Brejnrod, Asker ^e   Ansalone, Cecilia ^a   Duncan, Hazel ^b   Gervais, Lisa ^b   Tayler, Rachel ^b   Salmond, Jonathan ^f   Bolognini, Daniele ^a   Klopfleisch, Robert ^g   Gaya, Daniel R ^h   Milling, Simon ^a   Russell, Richard K ^b   Gerasimidis, Konstantinos ^a   more..

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^e Capital Region   (Denmark)

^f QUEEN ELIZABETH UNIVERSITY HOSPITAL   (United Kingdom)

^g FREIE UNIVERSITÄT BERLIN   (Germany)

^h GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Carbohydrate; Inflammatory Bowel Disease; Microbiota; Pediatric Trial

Indexed keywords

ACETIC ACID; ALCOHOL; BUTYRIC ACID; CALGRANULIN; CARBOHYDRATE; CXCL1 CHEMOKINE; GLUTEN; HLA B27 ANTIGEN; HLA B7 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTOSE; PROPIONIC ACID; RNA 16S; SATURATED FATTY ACID; SHORT CHAIN FATTY ACID; TASONERMIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; CROHN DISEASE; DIET THERAPY; DIETARY INTAKE; ENTERIC FEEDING; FEMALE; GLUTEN FREE DIET; HISTOPATHOLOGY; HUMAN; HUMAN EXPERIMENT; INTESTINE FLORA; LACTOSE FREE DIET; MALE; NONHUMAN; NORMAL HUMAN; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REMISSION; THERAPY EFFECT; YOUNG ADULT; ADOLESCENT; ANIMAL; BACTERIAL LOAD; BACTERIUM; CHILD; DISEASE MODEL; FECES; GENETICS; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; NUTRITIONAL STATUS; NUTRITIONAL VALUE; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SCOTLAND; TIME FACTOR; TRANSGENIC RAT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANIMALS; BACTERIA; BACTERIAL LOAD; CHILD; CROHN DISEASE; DISEASE MODELS, ANIMAL; ENTERAL NUTRITION; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HLA-B27 ANTIGEN; HLA-B7 ANTIGEN; HUMANS; MALE; NUTRITIONAL STATUS; NUTRITIVE VALUE; RATS, TRANSGENIC; RECURRENCE; REMISSION INDUCTION; SCOTLAND; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85063389989     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2018.12.002     Document Type: Article

References (37)

1. Sartor, R.B., Wu, G.D., Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology 152 (2017), 327–339.e4.
2. Lewis, J.D., Scott, F.I., Brensinger, C.M., et al. Increased mortality rates with prolonged corticosteroid therapy when compared with antitumor necrosis factor-alpha–directed therapy for inflammatory bowel disease. Am J Gastroenterol 113 (2018), 405–417.
3. Levine, A., Sigall Boneh, R., Wine, E., Evolving role of diet in the pathogenesis and treatment of inflammatory bowel diseases. Gut 67 (2018), 1726–1738.
4. Ruemmele, F.M., Veres, G., Kolho, K.L., et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis 8 (2014), 1179–1207.
5. Logan, M., Ijaz, U.Z., Hansen, R., et al. Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease. Aliment Pharmacol Ther 46 (2017), 1119–1120.
6. Gerasimidis, K., Bertz, M., Hanske, L., et al. Decline in presumptively protective gut bacterial species and metabolites are paradoxically associated with disease improvement in pediatric Crohn's disease during enteral nutrition. Inflamm Bowel Dis 20 (2014), 861–871.
7. Quince, C., Ijaz, U.Z., Loman, N., et al. Extensive modulation of the fecal metagenome in children with Crohn's disease during exclusive enteral nutrition. Am J Gastroenterol 110 (2015), 1718–1729 quiz 1730.
8. Gatti, S., Galeazzi, T., Franceschini, E., et al. Effects of the exclusive enteral nutrition on the microbiota profile of patients with Crohn's disease: a systematic review. Nutrients, 9(8), 2017.
9. Hart, A.L., Lomer, M., Verjee, A., et al. What are the top 10 research questions in the treatment of inflammatory bowel disease? A priority setting partnership with the James Lind Alliance. J Crohns Colitis 11 (2017), 204–211.
10. Stephen AM, Haddad, A.C., Phillips, S.F., Passage of carbohydrate into the colon. Direct measurements in humans. Gastroenterology 85 (1983), 589–595.
11. Buchanan, E., Gaunt, W.W., Cardigan, T., et al. The use of exclusive enteral nutrition for induction of remission in children with Crohn's disease demonstrates that disease phenotype does not influence clinical remission. Aliment Pharmacol Ther 30 (2009), 501–507.
12. Kitamura, S., Diet therapy and food exchange lists for diabetic patients. Diabetes Res Clin Pract 24:Suppl (1994), S233–S240.
13. Scientific Advisory Committee on Nutrition. Dietary reference values for energy. 2011, TSO, London.
14. Blake, M.R., Raker, J.M., Whelan, K., Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 44 (2016), 693–703.
15. Aiko, S., Grisham, M.B., Spontaneous intestinal inflammation and nitric oxide metabolism in HLA-B27 transgenic rats. Gastroenterology 109 (1995), 142–150.
16. Taurog, J.D., Richardson, J.A., Croft, J.T., et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 180 (1994), 2359–2364.
17. Ansalone, C., Utriainen, L., Milling, S., et al. Role of gut inflammation in altering the monocyte compartment and its osteoclastogenic potential in HLA-B27–transgenic rats. Arthritis Rheumatol 69 (2017), 1807–1815.
18. Schiffrin, E.J., El Yousfi, M., Faure, M., et al. Milk casein-based diet containing TGF-beta controls the inflammatory reaction in the HLA-B27 transgenic rat model. JPEN J Parenter Enteral Nutr 29 (2005), S141–S148 discussion S149–S150, S184–S188.
19. Asquith, M.J., Stauffer, P., Davin, S., et al. Perturbed mucosal immunity and dysbiosis accompany clinical disease in a rat model of spondylarthritis. Arthritis Rheumatol 68 (2016), 2151–2162.
20. Mahdi, B.M., Role of HLA typing on Crohn's disease pathogenesis. Ann Med Surg (Lond) 4 (2015), 248–253.
21. Turner, D., Griffiths, A.M., Walters, T.D., et al. Mathematical weighting of the Pediatric Crohn's Disease Activity Index (PCDAI) and comparison with its other short versions. Inflamm Bowel Dis 18 (2012), 55–62.
22. Ruemmele, F.M., Hyams, J.S., Otley, A., et al. Outcome measures for clinical trials in paediatric IBD: an evidence-based, expert-driven practical statement paper of the paediatric ECCO committee. Gut 64 (2015), 438–446.
23. Dieterle, F., Ross, A., Schlotterbeck, G., et al. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. Anal Chem 78 (2006), 4281–4290.
24. van den Berg, R.A., Hoefsloot, H.C., Westerhuis, J.A., et al. Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics, 7, 2006, 142.
25. Gerasimidis, K., Russell, R., Hansen, R., et al. Role of Faecalibacterium prausnitzii in Crohn's disease: friend, foe, or does not really matter?. Inflamm Bowel Dis 20 (2014), E18–E19.
26. Levine, A., Kori, M., Kierkus, J., et al. Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial. Gut 68 (2019), 239–247.
27. Ghouri, Y.A., Richards, D.M., Rahimi, E.F., et al. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol 7 (2014), 473–487.
28. Jansson, J., Willing, B., Lucio, M., et al. Metabolomics reveals metabolic biomarkers of Crohn's disease. PLoS One, 4, 2009, e6386.
29. Svolos, V., Gerasimidis, K., Buchanan, E., et al. Dietary treatment of Crohn's disease: perceptions of families with children treated by exclusive enteral nutrition, a questionnaire survey. BMC Gastroenterol, 17, 2017, 14.
30. Flint, A., Raben, A., Blundell, J.E., et al. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord 24 (2000), 38–48.
31. Varni, J.W., Bendo, C.B., Denham, J., et al. PedsQL gastrointestinal symptoms module: feasibility, reliability, and validity. J Pediatr Gastroenterol Nutr 59 (2014), 347–355.
32. Zheng, L., T'Kind, R., Decuypere, S., et al. Profiling of lipids in Leishmania donovani using hydrophilic interaction chromatography in combination with Fourier transform mass spectrometry. Rapid Commun Mass Spectrom 24 (2010), 2074–2082.
33. Zhang, T., Watson, D.G., Wang, L., et al. Application of holistic liquid chromatography-high resolution mass spectrometry based urinary metabolomics for prostate cancer detection and biomarker discovery. PLoS One, 8, 2013, e65880.
34. Creek, D.J., Jankevics, A., Burgess, K.E., et al. IDEOM: an Excel interface for analysis of LC-MS–based metabolomics data. Bioinformatics 28 (2012), 1048–1049.
35. Smith, C.A., Want, E.J., O'Maille, G., et al. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem 78 (2006), 779–787.
36. Scheltema, R.A., Jankevics, A., Jansen, R.C., et al. PeakML/mzMatch: a file format, Java library, R library, and tool-chain for mass spectrometry data analysis. Anal Chem 83 (2011), 2786–2793.
37. Klopfleisch, R., Multiparametric and semiquantitative scoring systems for the evaluation of mouse model histopathology—a systematic review. BMC Vet Res, 9, 2013, 123.